Cancers & treatments·Regimen libraryConsolidation

Blinatumomab

Checked 2026-09-09

B-ALL: MRD-positive, relapsed/refractory, or consolidation in frontline regimens (E1910, AALL1731)

One cycle

every 42 days × 2 · about 12 weeks in total

42-day cycle × 2 (consolidation) to 5 (about 12 weeks)Intravenous Continuous infusion

Components

Drug	Dose	Route	Days	Note
Blinatumomab Bispecific T-cell engager (CD19×CD3)	28 µg/day continuous infusion (9 µg/day days 1-7 of cycle 1 in relapsed disease)	IV	D1-28 (672 h infusion)

Cycles

2 (consolidation) to 5

42-day cycle

Emetogenicity

Minimal (<10%)

G-CSF

Not routine

Notes

Dexamethasone premedication; hospital admission for the first 3 days of cycle 1 and 2 days of cycle 2 for CRS and neurotoxicity.

Used in

Acute lymphoblastic leukaemia

Trials

TOWER ECOG-ACRIN E1910 COG AALL1731

Products

Blinatumomab

Source

TOWER, NEJM 2017; E1910, NEJM 2024

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.

Other regimens for these cancers

Inotuzumab ozogamicin

Relapsed or refractory CD22-positive B-ALL

every 21 days

Fludarabine + cyclophosphamide lymphodepletion, then CD19 CAR-T

Relapsed or refractory large B-cell lymphoma (second line if refractory or relapse within 12 months), B-ALL, follicular and mantle cell lymphoma

every 6 days

Imatinib

Chronic-phase CML; adjuvant GIST for 3 years after resection of high-risk tumours; metastatic GIST

every 28 days

Hyper-CVAD

Adult acute lymphoblastic leukaemia (with a tyrosine kinase inhibitor if Philadelphia-positive), Burkitt lymphoma and younger patients with mantle cell lymphoma

every 21 days × 8

All regimens Inotuzumab ozogamicin →